- Home
- HRMY vs BCRX Comparison
HRMY vs BCRX Comparison
Compare HRMY & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- BCRX
- Stock Information
- Founded
- HRMY 2017
- BCRX 1986
- Country
- HRMY United States
- BCRX United States
- Employees
- HRMY N/A
- BCRX N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRMY Health Care
- BCRX Health Care
- Exchange
- HRMY Nasdaq
- BCRX Nasdaq
- Market Cap
- HRMY 1.6B
- BCRX 1.7B
- IPO Year
- HRMY 2020
- BCRX 1994
- Fundamental
- Price
- HRMY $34.05
- BCRX $9.97
- Analyst Decision
- HRMY Strong Buy
- BCRX Buy
- Analyst Count
- HRMY 8
- BCRX 8
- Target Price
- HRMY $52.88
- BCRX $16.75
- AVG Volume (30 Days)
- HRMY 701.6K
- BCRX 5.9M
- Earning Date
- HRMY 05-06-2025
- BCRX 05-05-2025
- Dividend Yield
- HRMY N/A
- BCRX N/A
- EPS Growth
- HRMY 13.13
- BCRX N/A
- EPS
- HRMY 2.62
- BCRX N/A
- Revenue
- HRMY $744,852,000.00
- BCRX $503,485,000.00
- Revenue This Year
- HRMY $20.06
- BCRX $27.64
- Revenue Next Year
- HRMY $18.40
- BCRX $13.42
- P/E Ratio
- HRMY $13.10
- BCRX N/A
- Revenue Growth
- HRMY 20.62
- BCRX 41.67
- 52 Week Low
- HRMY $26.47
- BCRX $5.06
- 52 Week High
- HRMY $41.61
- BCRX $11.11
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- BCRX 65.89
- Support Level
- HRMY $29.82
- BCRX $9.83
- Resistance Level
- HRMY $30.61
- BCRX $11.11
- Average True Range (ATR)
- HRMY 1.12
- BCRX 0.51
- MACD
- HRMY 0.74
- BCRX 0.20
- Stochastic Oscillator
- HRMY 92.78
- BCRX 68.33
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.